JP6189299B2 - プリドピジン塩酸塩の新規な多形形態 - Google Patents

プリドピジン塩酸塩の新規な多形形態 Download PDF

Info

Publication number
JP6189299B2
JP6189299B2 JP2014528965A JP2014528965A JP6189299B2 JP 6189299 B2 JP6189299 B2 JP 6189299B2 JP 2014528965 A JP2014528965 A JP 2014528965A JP 2014528965 A JP2014528965 A JP 2014528965A JP 6189299 B2 JP6189299 B2 JP 6189299B2
Authority
JP
Japan
Prior art keywords
phenyl
propyl
methanesulfonyl
piperidine hydrochloride
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014528965A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014525470A (ja
JP2014525470A5 (enExample
Inventor
ゾネッソン、クラス
ピッテルコウ、トーマス
フロストルップ、ブライアン
ツィンマーマン、アンネ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceuticals International GmbH
Prilenia Neurotherapeutics Ltd
Original Assignee
Ivax International GmbH
Teva Pharmaceuticals International GmbH
Prilenia Neurotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ivax International GmbH, Teva Pharmaceuticals International GmbH, Prilenia Neurotherapeutics Ltd filed Critical Ivax International GmbH
Publication of JP2014525470A publication Critical patent/JP2014525470A/ja
Publication of JP2014525470A5 publication Critical patent/JP2014525470A5/ja
Application granted granted Critical
Publication of JP6189299B2 publication Critical patent/JP6189299B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2014528965A 2011-09-07 2012-09-06 プリドピジン塩酸塩の新規な多形形態 Expired - Fee Related JP6189299B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA201170496 2011-09-07
DKPA201170496 2011-09-07
US201161533550P 2011-09-12 2011-09-12
US61/533,550 2011-09-12
PCT/EP2012/067371 WO2013034622A1 (en) 2011-09-07 2012-09-06 Polymorphic form of pridopidine hydrochloride

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017107986A Division JP2017206516A (ja) 2011-09-07 2017-05-31 プリドピジン塩酸塩の新規な多形形態

Publications (3)

Publication Number Publication Date
JP2014525470A JP2014525470A (ja) 2014-09-29
JP2014525470A5 JP2014525470A5 (enExample) 2015-11-05
JP6189299B2 true JP6189299B2 (ja) 2017-08-30

Family

ID=47831564

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014528965A Expired - Fee Related JP6189299B2 (ja) 2011-09-07 2012-09-06 プリドピジン塩酸塩の新規な多形形態
JP2017107986A Withdrawn JP2017206516A (ja) 2011-09-07 2017-05-31 プリドピジン塩酸塩の新規な多形形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017107986A Withdrawn JP2017206516A (ja) 2011-09-07 2017-05-31 プリドピジン塩酸塩の新規な多形形態

Country Status (14)

Country Link
US (1) US9006445B2 (enExample)
EP (1) EP2753603B1 (enExample)
JP (2) JP6189299B2 (enExample)
KR (1) KR20140075703A (enExample)
CN (1) CN103958469B (enExample)
AU (1) AU2012306386B2 (enExample)
BR (1) BR112014005389A8 (enExample)
CA (1) CA2847736A1 (enExample)
EA (1) EA023462B1 (enExample)
ES (1) ES2639052T3 (enExample)
IL (1) IL231149A0 (enExample)
MX (1) MX343620B (enExample)
WO (1) WO2013034622A1 (enExample)
ZA (1) ZA201402492B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
MX2009011020A (es) 2007-04-12 2009-10-30 Nsab Af Neurosearch Sweden Ab Derivados de n-oxido y/o di-n-oxido de los estabilizadores/modulad ores del receptor de dopamina que exhiben perfiles mejorados de los efectos secundarios cardiovasculares.
NZ608120A (en) 2010-09-03 2014-12-24 Ivax Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
EP2787997A4 (en) 2011-12-08 2015-05-27 Ivax Int Gmbh HYDROBROMIDE SALT OF PRIDOPIDINE
BR112014024672A8 (pt) 2012-04-04 2018-04-03 Ivax Int Gmbh Composições farmacêuticas para terapia de combinação
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
CA2913781C (en) 2013-06-21 2022-05-10 Teva Pharmaceutical Industries Ltd. Use of pridopidine for treating huntington's disease
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
WO2016106142A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
EP3854785A1 (en) 2015-02-25 2021-07-28 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
WO2017048457A1 (en) * 2015-09-18 2017-03-23 Teva Pharmaceuticals Industries Ltd. Combination of laquinimod and pridopidine to treat multiple sclerosis
EP3419622B1 (en) 2016-02-24 2024-03-06 Prilenia Neurotherapeutics Ltd. Treatment of neurodegenerative eye disease using pridopidine
CN110012661A (zh) 2016-08-24 2019-07-12 普瑞尼亚医疗发展有限公司 普利多匹定用于治疗肌张力障碍的用途
IL311081A (en) 2016-08-24 2024-04-01 Prilenia Neurotherapeutics Ltd Use of pyridofidine to treat functional decline
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
ES2972205T3 (es) 2017-01-20 2024-06-11 Prilenia Neurotherapeutics Ltd Pridopidina para el tratamiento del síndrome x frágil
EP3357909A1 (en) 2017-02-02 2018-08-08 Sandoz AG Crystalline 4-[3-(methylsulfonyl)phenyl]-1-propyl-piperidine
HUE061505T2 (hu) 2017-08-14 2023-07-28 Prilenia Neurotherapeutics Ltd Módszer amyothrophiás lateralsclerosis kezelésére pridopidinnel
JP2020532517A (ja) 2017-08-30 2020-11-12 プリレニア ニューロセラピューティクス リミテッド 高濃度プリドピジン製剤
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
CA3075020C (en) 2017-09-08 2021-12-07 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
JP7585561B2 (ja) 2019-02-04 2024-11-19 プリレニア ニューロセラピューティクス リミテッド パーキンソン病およびパーキンソニズムに関連する他の疾患のための低用量プリドピジン
AU2020243692B2 (en) 2019-03-15 2023-03-02 Prilenia Neurotherapeutics Ltd. Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine
CN116472043A (zh) 2020-10-20 2023-07-21 普瑞尼亚神经治疗有限公司 普利多匹定和类似物用于治疗焦虑和抑郁的用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904723D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
SE9904724D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
GB0329236D0 (en) * 2003-12-17 2004-01-21 Arakis Ltd Crystalline forms of (+)- and (-)- erthro-mefloquine hydrochloride
CA2569843A1 (en) 2004-06-08 2005-12-22 A. Carlsson Research Ab New disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission
ES2659577T3 (es) 2004-10-13 2018-03-16 Teva Pharmaceuticals International Gmbh Proceso para la síntesis de 4-(3-metanosulfonilfenil)-1-N-propil-piperidina
SE529246C2 (sv) 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
TW200804241A (en) * 2006-02-24 2008-01-16 Novartis Ag New salt
MX2009011020A (es) 2007-04-12 2009-10-30 Nsab Af Neurosearch Sweden Ab Derivados de n-oxido y/o di-n-oxido de los estabilizadores/modulad ores del receptor de dopamina que exhiben perfiles mejorados de los efectos secundarios cardiovasculares.
US20100197712A1 (en) 2007-06-18 2010-08-05 Arvid Carlsson Use of dopamine stabilizers
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
NZ608120A (en) 2010-09-03 2014-12-24 Ivax Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
EP2787997A4 (en) 2011-12-08 2015-05-27 Ivax Int Gmbh HYDROBROMIDE SALT OF PRIDOPIDINE
BR112014024672A8 (pt) 2012-04-04 2018-04-03 Ivax Int Gmbh Composições farmacêuticas para terapia de combinação
MX2015003812A (es) 2012-09-27 2015-07-17 Teva Pharma Combinacion de rasagilina y pridopidina para tratar trastornos neurodegenerativos, en particular enfermedad de huntington.
US20150209346A1 (en) 2012-09-27 2015-07-30 Teva Pharmaceutical Industries, Ltd. Combination of laquinimod and pridopidine for treating neurodegenerative disorders, in particular huntington's disease

Also Published As

Publication number Publication date
ZA201402492B (en) 2015-07-29
AU2012306386A1 (en) 2014-04-17
NZ623344A (en) 2015-10-30
JP2014525470A (ja) 2014-09-29
KR20140075703A (ko) 2014-06-19
ES2639052T3 (es) 2017-10-25
BR112014005389A2 (pt) 2017-03-28
EP2753603A1 (en) 2014-07-16
CN103958469A (zh) 2014-07-30
MX343620B (es) 2016-11-11
JP2017206516A (ja) 2017-11-24
EA201490569A1 (ru) 2014-09-30
MX2014002731A (es) 2014-04-30
WO2013034622A1 (en) 2013-03-14
IL231149A0 (en) 2014-04-30
CN103958469B (zh) 2016-04-20
HK1199728A1 (en) 2015-07-17
BR112014005389A8 (pt) 2018-04-03
EP2753603B1 (en) 2017-06-21
AU2012306386B2 (en) 2017-06-15
US9006445B2 (en) 2015-04-14
EA023462B1 (ru) 2016-06-30
CA2847736A1 (en) 2013-03-14
US20140315951A1 (en) 2014-10-23

Similar Documents

Publication Publication Date Title
JP2017206516A (ja) プリドピジン塩酸塩の新規な多形形態
AU2014239995B2 (en) Salt of omecamtiv mecarbil and process for preparing salt
WO2018197653A1 (en) Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production
CN104470920A (zh) 固态形式的维罗菲尼胆碱盐
CN104470911A (zh) 氨基甲酸酯/脲衍生物
KR20240000540A (ko) (s)-n-(3-(2-(((r)-1-하이드록시프로판-2-일)아미노)-6-모르폴리노피리딘-4-일)-4-메틸페닐)-3-(2,2,2-트리플루오로에틸)피롤리딘-1-카르복스아미드 및 이의 염의 고체 상태 형태
EP3430004A1 (en) Solid state forms of nilotinib salts
US20160046615A1 (en) Novel Crystal Form of Dabrafenib Mesylate and Preparation Method Thereof
US20230279017A1 (en) Salt and solid forms of tabernanthalog
JP6610793B2 (ja) 環状アミン誘導体の結晶及びその医薬用途
JP7152122B2 (ja) エダラボン塩
JP2019504046A (ja) チエノピリミジン化合物の結晶形
US10513500B2 (en) Crystalline forms of Lesinurad
US11208382B2 (en) Entinostat-containing compound, crystal form of compound thereof, and preparation method therefor and pharmaceutical composition thereof
TW201811326A (zh) ４－氰基－ｎ－（２－（４，４－二甲基環己－１－烯－１－基）－６－（２，２，６，６－四甲基四氫－２ｈ－哌喃－４－基）吡啶－３－基）－１ｈ－咪唑－２－甲醯胺之鹽形式
WO2012125993A1 (en) Solid state forms of rilpivirine base, and rilipivirine salts
JP2013531662A (ja) カルシウム模倣化合物の新規多形
EP3587421A1 (en) Crystalline forms of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-alpha]pyrazin-1-yl-n-(pyridin-2-yl)benzamide
JP2014501753A (ja) ３−クロロ−４［（２ｒ）−２−（４−クロロフェニル）−４−［（１ｒ）−１−（４−シアノフェニル）エチル］−１−ピペラジニル］−ベンゾニトリルの多形、前記多形を含む医薬組成物および使用方法、ならびにその調製方法
HK1199728B (en) Polymorphic form of pridopidine hydrochloride
NZ623344B2 (en) Polymorphic form of pridopidine hydrochloride
JP2013531661A (ja) カルシウム模倣化合物の新規多形
WO2016101912A1 (zh) 一种表皮生长因子受体激酶抑制剂的盐的晶型及其制备方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150907

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150907

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160412

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160414

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160711

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160802

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161102

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170531

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170616

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170704

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170802

R150 Certificate of patent or registration of utility model

Ref document number: 6189299

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees